PharmaStem Patents Confirmed after Reexamination by Patent Office

05-Apr-2007

PharmaStem Therapeutics, Inc. announced that the United States Patent and Trademark Office has confirmed all the claims in its patents regarding umbilical cord blood stem cells. The Patent Office had previously granted third party requests to reexamine U.S. Patent Nos. 5,004,681, 5,192,553, 6,461,645 and 6,569,427, and has now concluded, after reexamination, that all of the claims are valid.

"Considering the pioneering research of our inventors which eventually led to the creation of the private and public cord blood banking industry, I was always confident that the Patent Office would confirm the validity of our patents and I am gratified that all three senior patent examiners involved in the reexamination reached the same conclusion," said Nicholas Didier, CEO and President of PharmaStem. "It is important for our licensees - of which there are over 20 - to know that the patents they have licensed are valid, and can protect them."

Although the majority of private cord blood banks are licensed under PharmaStem's patent portfolio, ViaCord (VIAC), Cryo-Cell (CCEL), CBR Systems and CorCell do not have a license to practice the inventions claimed in PharmaStem's patents.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...